法语系药物遗传学网络 (RNPGx) 在药物遗传学中通过基因定型或测序进行基因组分析的建议
Nicolas Picard1, Estelle Ayme-Dietrich2, Sylvie Quaranta3
1Department of Pharmacology, Toxicology and Pharmacovigilance, Inserm 1248 P&T, CHU Limoges, Limoges, France.
Fundamental & clinical pharmacology
|January 6, 2026
概括
这项研究制定了协调的建议,用于设计药物遗传学面板,确定临床相关的基因和区域,以改善患者护理. 该框架支持从全外体或全基因组测序数据的解释.
科学领域:
- 临床药理学 临床药理学
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 药物遗传学测试越来越多地被整合到临床实践中,经常使用多基因组.
- 为了有效设计和实施这些面板,需要采用标准化的方法.
研究的目的:
- 为多基因药物遗传学面板的设计和分析实施制定协调一致的建议.
- 根据证据,治疗用途和技术兼容性来定义临床相关的基因和感兴趣的区域 (ROI).
主要方法:
- 法语系药物遗传学网络 (RNPGx) 在五个治疗领域使用结构化,基于证据的评分系统评估了81个基因.
- 一个25分评分系统整合了药物遗传学重要性,指导方针和专家共识.
- 感兴趣的区域根据临床可行性和测试范围被分为三个分析类.
主要成果:
- 一个28基因核心面板最终完成.
- 第1类包括76种优先变异,而第2类包括62种额外的变异,包括对CYP2D6.6的扩展分析.
- 为18个基因建立了3类的资格,支持更广泛的基因组分析.
结论:
- RNPGx建议为药物遗传学面板设计提供了一个灵活的框架.
- 该框架有助于从全外体和全基因组测序中提取和解释临床应用的药物遗传数据.
更多相关视频
相关概念视频
Epistasis Analysis
4.9K
Although Mendel chose seven unrelated traits in peas to study gene segregation, most traits involve multiple gene interactions that create a spectrum of phenotypes. When the interaction of various genes or alleles at different locations influences a phenotype, this is called epistasis. Epistasis often involves one gene masking or interfering with the expression of another (antagonistic epistasis). Epistasis often occurs when different genes are part of the same biochemical pathway. The...
4.9K
Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121


